EDAP TMS S.A. is a French medical device company specializing in therapeutic ultrasound, including high-intensity focused ultrasound (HIFU) for prostate cancer and lithotripsy for kidney stones, founded in 1979. The company’s Focal One system delivers robotic HIFU treatment guided by transrectal ultrasound imaging and received FDA clearance for prostate cancer treatment in 2018. EDAP TMS is publicly traded on the NASDAQ exchange under the ticker EDAP.